Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diagnostic tool could speed up treatment for deadly heart infection

NCT ID NCT07682389

Diagnosis Sponsor: I.M. Sechenov First Moscow State Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests whether adding advanced molecular tests (like PCR and DNA sequencing) to standard blood cultures helps doctors identify the cause of infective endocarditis—a serious heart valve infection—more quickly. The goal is to see if this leads to more patients receiving the right antibiotics within 14 days. The trial involves 128 adults with suspected or confirmed infective endocarditis, comparing the new diagnostic algorithm to standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Molecular tests (PCR, sequencing)
What this could lead to
If successful, this diagnostic algorithm could help doctors prescribe targeted antibiotics sooner for infective endocarditis, potentially reducing complications.
What could go wrong
This is a relatively small trial (128 participants) testing a diagnostic approach, not a treatment itself. The algorithm may not improve outcomes or may be difficult to implement in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed consent, * Age ≥ 18, * IE (definite or possible per the 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis) Exclusion Criteria: * Pregnancy/breastfeeding * Unconfirmed or rejected IE diagnosis, * Very high risk of death within 14 days due to severe complications of the main or concomitant disease(s), according to the physician's opinion; * Prior use of antibiotic therapy (except documented treatment failure).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infective endocarditis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endocarditis infective endocarditis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infective endocarditis Microbiology

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • A.N. Bakulev National Medical Research Center for Cardiovascular Surgery of the Russian Ministry of Health

    NOT_YET_RECRUITING

    Moscow, Russia

  • City Clinical Hospital Named After S. S. Yudin

    RECRUITING

    Moscow, Russia

  • City Clinical Hospital №67 Named After L. A. Vorokhobova

    RECRUITING

    Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.